Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
46.35
-1.30 (-2.73%)
Jul 16, 2025, 4:08 PM HKT
Market Cap51.09B
Revenue (ttm)6.98B
Net Income (ttm)359.76M
Shares Outn/a
EPS (ttm)0.42
PE Ratio142.00
Forward PE42.02
Dividend0.32 (0.67%)
Ex-Dividend DateJun 12, 2025
Volume5,070,445
Average Volume4,769,886
Open48.30
Previous Close47.65
Day's Range46.00 - 48.30
52-Week Range22.30 - 58.80
Beta0.78
RSI64.94
Earnings DateAug 29, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.